| Literature DB >> 28859793 |
Robert S Rosenson1, Steven Baker2, Maciej Banach3, Kenneth M Borow4, Lynne T Braun5, Eric Bruckert6, Liam R Brunham7, Alberico L Catapano8, Marshall B Elam9, G B John Mancini10, Patrick M Moriarty11, Pamela B Morris12, Paul Muntner13, Kausik K Ray14, Erik S Stroes15, Beth A Taylor16, Valerie H Taylor17, Gerald F Watts18, Paul D Thompson19.
Abstract
Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.Entities:
Keywords: cardiovascular disease; low-density lipoprotein; myalgia; myopathy; statin intolerance
Mesh：
Substances：
Year: 2017 PMID： 28859793 DOI： 10.1016/j.jacc.2017.07.752
Source DB: PubMed Journal: J Am Coll Cardiol ISSN： 0735-1097 Impact factor: 24.094